Opendata, web and dolomites

BIOFOSTE

Clinical validation of a BIOmarker panel For OSTEoarthritis diagnosis: BIOFOSTE

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "BIOFOSTE" data sheet

The following table provides information about the project.

Coordinator
ISTITUTO DI RICERCA TRASLAZIONALE PER L'APPARATO LOCOMOTORE NICOLA CERULLI - LPMRI - SRL 

Organization address
address: VIA A. EINSTEIN 12L
city: AREZZO
postcode: 52100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.irtal.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ISTITUTO DI RICERCA TRASLAZIONALE PER L'APPARATO LOCOMOTORE NICOLA CERULLI - LPMRI - SRL IT (AREZZO) coordinator 50˙000.00
2    CYANAGEN SRL IT (BOLOGNA) participant 0.00

Map

 Project objective

OSTEoarthritis (OA) is the most common degenerative joint disease in the middle-age and elderly population, that leads to disability in 40% of the adults over 70 years. The clinical manifestations of OA are pain and functional disability that can limit the normal activities of daily life and lead to depression and isolation. OA assessment is mainly carried out using radiography, which is the gold standard for diagnostic purposes. However this approach has poor sensitivity and diagnosis is obtained only when the articular cartilage has degraded significantly. Based on the extremely high economic burden, quantified in tens of billions of euro in the world, which will tend to increase in the future years, there is a need to validate OA biomarkers. In fact, although several proteins and miRNAs have been described as being altered and correlated with OA progression, there are no currently available BIOmarkers for OA diagnosis. This project concerns the development and clinical validation of a combined panel composed of proteins and miRNAs, which have been found altered in OA patients, combined with a new marker identified by IRTAL and a patented secondary chemiluminescence ELISA enhancer developed by CYANAGEN to ensure a high sensitivity for an early OA diagnosis. Our final goal is to validate and commercialize an IVD kit that may help the clinicians make an early diagnosis or predict the outcome/prognosis of OA patients, to improve the patients' quality of daily life while decreasing the related economic losses due to unproductivity, absenteeism, disability and also in terms of surgical procedures and hospitalization resources for the Health care systems. This project will allow involved SMEs to enter in the IVD market seizing the related business opportunity. In Phase 1 of the project we will select the optimal biomarkers, determine the market and clinical utility of the diagnostic test

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOFOSTE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOFOSTE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More